Eric Litjens

[Prilenia @PrileniaTx]

In one of the biggest all-private deals of the year, totaling up to €500 million @PrileniaTx and @ferrerforgood announced that they’ve joined forces to advance #pridopidine in Europe and other select international markets through a commercialization and co-development agreement. #Pridopidine for #HuntingtonsDisease is currently under review by the EMA with a CHMP opinion expected in 2H2025. This half-billion euro deal supports the accelerated development and expansion of pridopidine into additional #neurodegenerative indications, such as #ALS. Read the PR: https://t.co/rY5YIF9DH9

[Amylyx @AmylyxPharma]

#DYK that there are no approved therapies for post-bariatric hypoglycemia (PBH), a potentially life-threatening complication of bariatric surgery?

PBH is thought to be caused by exaggerated secretion of glucagon-like peptide-1 (GLP-1) leading to hypersecretion of insulin and a rapid drop in blood sugar.

Symptoms can result in major disruptions to daily living, including falls, motor vehicle accidents, and job and income loss.

[Eric Litjens @EricLitjens]

#RareDiseaseDay2024 #TogetherForALS

[EUpALS @EUpALS]

Today is #RareDiseaseDay.
Did you know that #ALS is #Rarebutnotsorare ?
Learn in the infographic about this lethal debilitating disease that needs funding and accelerated pathways for further research and multidisciplinary care.
#EUpALStogetherwearestrong in fight against ALS.

[Amylyx @AmylyxPharma]

CENTAUR remains the first and only to show both the slowing of disease progression and extending overall survival in a single #ALS trial. See how we are building on learnings from that trial to move forward.

[Amylyx @AmylyxPharma]

February 29th is #RareDiseaseDay. Rare diseases affect 3-6% of the global population, including 200,000 people who are living with motor neuron diseases such as ALS. Amylyx is dedicated to bringing people with rare diseases together. #ColorMeRare #TogetherForALS

[Zach Gelb @ZachGelb]

About to do the ALS ice bucket challenge with @M_Ryan02 on radio row. 10 years of the challenge.

https://t.co/AOlD7fbYyU

[Amylyx @AmylyxPharma]

Join us on Feb 21 for our second Amylyx Aktuell HCP webinar, as part of our series on #neurodegenerative diseases. Experts in #neuromuscular diseases Prof. Dr. Dorst and Dr. Boentert will discuss practical aspects of ventilation for #PLWALS.

https://t.co/4QcEtofNqO

[Amylyx @AmylyxPharma]

Today we announced we’ve completed enrollment of HELIOS, our Phase 2 #clinicaltrial studying the treatment of #Wolframsyndrome (WS). Thank you to all those who partnered with us on this important milestone. Learn more: https://t.co/q0qylHIk62

[Eric Litjens @EricLitjens]

https://t.co/4U42b4K7Fx

[Amylyx @AmylyxPharma]

We’re committed to our mission in ending the suffering caused by #neurodegenerative diseases like #ALS. Whether you're a person living with ALS, a friend, or family member, visit our resource page for support and community. https://t.co/Cs6tgaA3kV

[Amylyx @AmylyxPharma]

Today we announced the first participant dosed in the largest
#progressivesupranuclearpalsy (#PSP) study to date. This Phase 3 #clinicaltrial will enroll ~600 participants across the U.S., Canada, the EU, the UK, and Japan. Read more:

[Amylyx @AmylyxPharma]

#WolframSyndrome (WS) is among the lesser known #neurodegenerative diseases and is characterized by juvenile diabetes mellitus, optic atrophy and deafness. Learn about the causes and symptoms that affect those living with WS.

[Amylyx @AmylyxPharma]

“Why do neurons die?”
That one question jumpstarted what evolved into the global company Amylyx is today. We’re relentless in our pursuit to end the suffering caused by #ALS and other #neurodegenerative diseases. Learn about us and our endless curiosity: https://t.co/m3HFvvky1u

[Amylyx @AmylyxPharma]

Today we announced several abstracts on the potential treatment of ALS and other neurodegenerative diseases will be presented at the 34th International Symposium on ALS/MND. Learn more: https://t.co/XwVJBrEXZV

[Amylyx @AmylyxPharma]

We’re excited to welcome Dr. Camille L. Bedrosian to #TeamAmylyx as Chief Medical Officer. Dr. Bedrosian brings nearly 30 yrs of experience addressing unmet needs for people with rare & serious diseases. Learn more: https://t.co/StmYbFPGro

[EUpALS @EUpALS]

A must read: EUpALS, together with #ENCALS #TRICALS #EUALSCoalition and other valuable initiatives, is integrated in an Editorial of The Lancet Neurology November 2023 'Speeding up research to improve the lives of people with ALS'. True recognition of the European ALS Community!

[Amylyx @AmylyxPharma]

DYK #Wolframsyndrome (WS) has no disease-modifying treatment options? We are committed to exploring treatments for challenging #neurodegenerative diseases like WS.
Learn more below.

[Amylyx @AmylyxPharma]

#ProgressiveSupranuclearPalsy (#PSP) is a rare #neurodegenerative disease. Let’s break down the meaning of the name.

[EFPIA @EFPIA]

Data shows that Europe has lost its place as leader in medical innovation. The #EUPharmaLegislation is a golden opportunity to reverse the trends of the last 25 yrs. However, as currently written, the  proposals would have a negative impact on 💊R&D in Europe #POLITICOHealthCare